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based on primary ICD-9-CM discharge diagnosis of ICH
(431.xx). Patient-level information included demographics
(including race/ethnicity: White, Black, Hispanic, Asian), hospi-
tal characteristics, comorbidities, primary payer, admission
source, discharge destination, DRG, length of stay (LOS), and
hospital charges. Costs were estimated by applying hospital-
speciﬁc cost-to-charge ratios to charges. Adjusted LOS and cost
(controlling for age, in-hospital mortality, and other covariates)
by race/ethnicity were estimated using multivariate least-squares
regression. RESULTS: Black, Hispanic, and Asian patients with
a primary diagnosis of ICH at discharge were signiﬁcantly
younger, on average, than White patients (73.5 vs. 61.2, 63.9,
and 67.9 years, respectively; p < 0.01 for all comparisons). Black
and Hispanic patients experienced longer hospital stays (p <
0.01) and incurred higher costs (p < 0.01), on average, than
White patients. Among Black and Hispanic patients, adjusted
length of stay (mean costs) per discharge were approximately 2.3
days ($1400) and 1.7 ($3400) higher, respectively, as compared
to White patients. Asian patients had longer adjusted stays (2.6
additional days, p < 0.01) and higher costs ($830, p < 0.31).
CONCLUSIONS: There are meaningful differences in length of
stay and cost of ICH hospitalizations among patients with dif-
ferent race/ethnicity. Improved acute treatment of stroke in this
high-risk population may help to improve overall outcomes in
these subgroups.
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OBJECTIVES: To assess the association between
overweight/obesity and employment to population ratio (E/P
Ratio), hourly wage, and annual income in the U.S. METHODS:
Adults (age 18–64) in the 2000–2002 Medical Expenditure 
Panel Survey (MEPS) were classiﬁed as normal weight
(BMI:18.5–24.9), overweight (BMI:25–29.9), and obese (BMI:
>= 30). Underweight (BMI < 18.5) individuals were excluded.
E/P ratio, hourly wage, annual income, and poverty status of the
overweight and obese adults were compared to that of the
normal weight adults, respectively, adjusting for demographic
characteristics using a stratiﬁcation matching method. MEPS
sampling weights were applied to ensure nationally representa-
tive estimates. The analyses were also conducted for population
subgroups deﬁned by gender, race, ethnicity, and physical activ-
ity. RESULTS: The study sample includes 35,989 adults, with
13,744 normal weight, 13,321 overweight, and 8,924 obese. The
E/P ratio was 87.1% for the overweight sample, 1.8% higher (p
< 0.01) than the normal weight sample; and 82.4% for the obese
sample, 1.7% lower (p < 0.01) than the normal weight sample.
The obese sample made $1.63 less per hour (p < 0.01), and
$3338 less annually compared to the normal weight sample (p
< 0.01). Compared to the normal weight sample, obese adults
were more likely to be poor. No signiﬁcant difference of annual
income and poverty level were found between the overweight
and the normal weight sample. Systematic differences between
different population subgroups were found. CONCLUSIONS:
Obese adults are less likely to be employed, have lower annual
incomes and hourly wages, and are more likely to be poor than
normal weight adults.
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OBJECTIVE: To examine the incidence of overactive bladder
(OAB)-related clinical events for elderly patients receiving phar-
macotherapy compared with those receiving non-pharmacologic
management. METHODS: Data were obtained from the Phar-
Metrics Patient-Centric Database on continuously beneﬁt-
eligible patients aged ≥65 years diagnosed with OAB between
January 2002 and December 2003. Patients were categorized
into 2 cohorts: those receiving pharmacotherapy, including long-
acting tolterodine, or immediate- or extended-release oxybutynin
and those receiving non-pharmacologic management. Patients
were matched 1 :1 by the estimated propensity score for OAB
pharmacotherapy using a logistic regression model that included
selected demographic and clinical characteristics. The incidence
of clinical events, including assessment of depression, urinary
tract infections (UTIs), and falls or fractures was evaluated.
Crude event rates were reported, as well as the risk of an event
using Cox proportional hazards models adjusting for important
demographic and clinical characteristics. RESULTS: A total of
1681 matched pairs were identiﬁed. Mean ± SD age was 78 ± 8
years; 60% were women. After matching, differences in baseline
patient characteristics between cohorts were not signiﬁcant. The
incidence of depression (10.2% for pharmacotherapy vs 11.0%
for non-pharmacologic management; p = NS) and fractures
(8.6% vs 10.1%; p = NS) was numerically lower in the drug-
treated cohort, and the incidence of UTI was signiﬁcantly lower
(28.1% vs 36.5%; p < 0.0001). Adjusted rates using Cox pro-
portional hazards models were similar, with no difference in the
risk of depression (hazard ratio [HR] = 0.980; 95% conﬁdence
interval [CI], 0.795–1.208; p = NS) or fractures (HR = 0.863;
95% CI, 0.691–1.079; p = NS) between the cohorts, and the risk
of UTI was 28% lower among pharmacotherapy patients (HR =
0.718; 95% CI, 0.636–0.810; p < 0.0001). CONCLUSIONS:
Pharmacotherapy may impart selected clinical beneﬁts for some
elderly patients with OAB compared with non-pharmacologic
management. Careful consideration should be given to the selec-
tion of treatment approaches in this high-risk population.
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OBJECTIVES: We examined the effects of statin prescription
drug copayments and statin adherence on cardiovascular uti-
lization patterns, medical and prescription drug expenditures
and other outcomes of statin therapy. METHODS: The
2001–2003 MarketScan database was used to study the health
care utilization and expenditure patterns of continuously
enrolled statin users in employer sponsored health plans. We
analyzed the utilization patterns of 93,296 continuing users who
had previously ﬁlled at least one statin prescription in 2000 and
24,128 users who were new to statin therapy in the ﬁrst half of
2001. A two-stage estimation approach consisted of a multi-
variate logit model estimating the relationship between copay-
